Uncategorized

Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple Myeloma

2 months ago
by David Miller
945 Views

TUESDAY, Oct. 8, 2024 — Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online Oct. 4 in Blood.
Surbhi Sidana, M.D…

TUESDAY, Oct. 8, 2024 — Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online Oct. 4 in Blood.
Surbhi Sidana, M.D…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]